Therapeutic Effect of Quercetin and the Current Treatment of Erosive and Atrophic Oral Lichen Planus
|ClinicalTrials.gov Identifier: NCT01375101|
Recruitment Status : Unknown
Verified July 2011 by Mashhad University of Medical Sciences.
Recruitment status was: Recruiting
First Posted : June 17, 2011
Last Update Posted : July 26, 2011
Lichen planus (LP) is a common chronic inflammatory mucocutaneous disease with an immunologic etiology ,which has number of different clinical forms. Alternative natural or herbal origine drugs with antioxidant and anti-inflammatory properties have been used individually or in combination with systemic corticosteroids in order to decrease adverse drug reactions.
This study was conducted to evaluate the effect of quercetin on treatment of erosive -atrophic lesions of oral lichen planus (OLP).
|Condition or disease||Intervention/treatment||Phase|
|Atrophic Oral Lichen Planus Erosive Oral Lichen Planus||Drug: placebo Drug: Quercetin||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Study Start Date :||April 2010|
|Estimated Primary Completion Date :||September 2011|
|Estimated Study Completion Date :||September 2011|
Active Comparator: quercetin
quercetin is one of flavonoids , and having therapeutical anti-inflammatory and antioxidant action
The patient is directed to digest quercetin hydrate capsule two times a day,until one mouth
Placebo Comparator: placebo
placebo capsul is produced with lactose for using in placebo/ control group.
The patient is directed to use placebo capsule two times a day, ,until the one mouth
- the effects of this Drug on OLP measured with VAS scale for pain and evaluation of intensity of lesions. [ Time Frame: 2 months ]In the present work the Analogical Visual Scale is used TO evaluate pain,and we also record the intensity of lesions weekly and any side effect of this Drug
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01375101
|Contact: maryam amirchaghmaghi, assistant firstname.lastname@example.org|
|Iran, Islamic Republic of|
|Mashhad university of Medical science, Research Center of oral and maxillofacial medicine||Recruiting|
|Mashhad, Khorasan Razavi, Iran, Islamic Republic of, 91735|
|Contact: maryam amirchaghmaghi, assistant professor 0098-0511882901 email@example.com|